on this page
Patient eligibility
Treatment with sonidegib and vismodegib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 for a patient with metastatic or locally advanced basal cell carcinoma.
Patients must be eligible for the PBS and meet the relevant restriction criteria..
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing sonidegib and vismodegib.
Applications
Initial treatment
Make all initial applications for authority approval to prescribe sonidegib or vismodegib for the treatment of metastatic or locally advanced BCC in writing and either:
- upload through Health Professional Online Services (HPOS)
- post to the PBS Complex Drugs Programs.
All applications must include the completed:
- authority prescription form(s)
- Metastatic or locally advanced basal cell carcinoma - sonidegib or vismodegib Initial PBS authority application
- relevant attachments.
Continuing treatment
Make all applications for continuing authority approval to prescribe sonidegib or vismodegib for the treatment of metastatic or locally advanced BCC in writing and either:
- upload through HPOS
- post to the PBS Complex Drugs Programs.
All applications must include the completed:
- authority prescription form(s)
- Metastatic or locally advanced basal cell carcinoma - sonidegib or vismodegib Continuing PBS authority application
- relevant attachments.
Further information
Call the PBS Complex Drugs Programs enquiry line for more information.